Mayne Pharma: Yet Another Transformational Acquisition
Mayne Pharma’s latest US acquisition is expected to be strongly accretive to earnings in FY17. We estimate 31% EPS accretion. The entitlement offer to existing shareholders is offered at $1.28 which represents a 32% discount to target price of $1.89. The transaction elevates MYX to become one of the larger producers of generic medicines in the US market. We expect further bolt on acquisitions in the near term in the specialty brands division. We recommend existing shareholders take up their full entitlement offer. Full report attached and John Hester provides a video summary
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
Already have an account? Sign in here
Advertisement
Bell Potter Securities is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to a diversified client base that includes individuals, institutions and corporations.
Never miss an update
Get the latest insights from me in your inbox when they’re published.
Stockbroker
Bell Potter Securities is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to a diversified client base that includes individuals, institutions and corporations.
Expertise
Stockbroker
Bell Potter Securities is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to a diversified client base that includes individuals, institutions and corporations.
Please sign in to comment on this wire.